Gowsia Akhter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gowsia Akhter has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hinna Hamid
Department of Chemistry, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi, 110062, India
2 shared publications - Kalicharan Sharma
School of Pharmacy, Graphic Era Hill University Dehradun India
2 shared publications - Mohammad Sarwar Alam
Department of Chemistry, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi, 110062, India
2 shared publications - Angamuthu Selvapandiyan
Department of Molecular Medicine, Jamia Hamdard, New Delhi, India
1 shared publication Ayan Kumar Das
Department of Microbiology Hamdard Institute of Medical Sciences and Research Jamia Hamdard Hamdard Nagar New Delhi 110062 India
1 shared publicationBharti Dhawan
Department of Chemistry School of Chemical and Life Sciences Jamia Hamdard Hamdard Nagar New Delhi 110062 India
1 shared publication
Latest Publications
- 1 September 2025
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (31) , 6900-6928
Design and Synthesis of Benzimidazole Carboxamide Cysteine Protease Inhibitors as Promising Anti-leishmanial Agents
Introduction: More than 20 protozoan species of Leishmania are responsible for causing Leishmaniasis, an infection spread by blood-feeding phlebotomine sandflies. A narrow pool of drugs is currently available rendering the current drug stratagem to treat this infection . Development of novel, less toxic, and more effective regimens is thus a need of the hour. Design and synthesis of benzo[d]imidazole carboxamides as agents to combat Leishmaniasis are also required. Methods: 14 benzo[d]imidazole carboxamides were synthesized and gauged against L. donovani promastigotes and intramacrophage amastigote forms. All of the tested compounds exhibited significant anti-promastigote properties with IC50 well below 10 uM. Compounds 4a, 4b, and 4d, showing the highest anti-parasitic activity against promastigote forms (IC50 0.91- 1.33 μM), were also found to be associated with better anti-leishmanial potential (IC50 0.78- 1.67 μM) against the intramacrophage amastigotes comparable to Amphotericin-B (0.13 μM), a drug used for Leishmaniasis. Compound (4a), namely N-(2-(trifluoromethyl)-1Hbenzo[ d]imidazol-5-yl)benzo[d][1,3]-5-carboxamide-dioxole, was found to be most potent against L. donovani amastigotes among all the tested compounds, and demonstrated better antileishmanial properties (IC50 0.78 μM) when compared to the standard. Compound 4a was also assessed for its toxicity profile against THP-1 human monocytic cells. To establish the molecular target(s) in silico, molecular docking studies were performed against cysteine protease, a putative virulence factor of Leishmania parasites, and nucleoside diphosphate kinase, an enzyme with a critical role in nucleotide recycling, also associated with resistance in Leishmania strains. Compound 4a showed better binding affinity than the standard to these targets; furthermore, the molecular dynamic simulation studies further affirmed the stability of compound 4a, within the active site of the targets. In vitro, cysteine protease inhibitory activity (IC50 8.53 μM) using Bz-Arg-AMC hydrochloride fluorogenic peptide substrate established the promising potential of 4a as a cysteine protease inhibitor. Results: Computational ADMET analysis indicated appropriate pharmacokinetic profile and physicochemical characteristics for all members of the synthesized library. Conclusion: Both in vitro and in silico studies indicate that the synthesized imidazole carboxamides can act as potent hits and that N-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5- yl)benzo[d][1,3]-5-carboxamide-dioxole 4a can be an effective hit molecule which can be further developed into potent lead molecule (s) to fight Leishmania donovani.
- 1 September 2025
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (31) , 6900-6928
Design and Synthesis of Benzimidazole Carboxamide Cysteine Protease Inhibitors as Promising Anti-leishmanial Agents
Introduction: More than 20 protozoan species of Leishmania are responsible for causing Leishmaniasis, an infection spread by blood-feeding phlebotomine sandflies. A narrow pool of drugs is currently available rendering the current drug stratagem to treat this infection . Development of novel, less toxic, and more effective regimens is thus a need of the hour. Design and synthesis of benzo[d]imidazole carboxamides as agents to combat Leishmaniasis are also required. Methods: 14 benzo[d]imidazole carboxamides were synthesized and gauged against L. donovani promastigotes and intramacrophage amastigote forms. All of the tested compounds exhibited significant anti-promastigote properties with IC50 well below 10 uM. Compounds 4a, 4b, and 4d, showing the highest anti-parasitic activity against promastigote forms (IC50 0.91- 1.33 μM), were also found to be associated with better anti-leishmanial potential (IC50 0.78- 1.67 μM) against the intramacrophage amastigotes comparable to Amphotericin-B (0.13 μM), a drug used for Leishmaniasis. Compound (4a), namely N-(2-(trifluoromethyl)-1Hbenzo[ d]imidazol-5-yl)benzo[d][1,3]-5-carboxamide-dioxole, was found to be most potent against L. donovani amastigotes among all the tested compounds, and demonstrated better antileishmanial properties (IC50 0.78 μM) when compared to the standard. Compound 4a was also assessed for its toxicity profile against THP-1 human monocytic cells. To establish the molecular target(s) in silico, molecular docking studies were performed against cysteine protease, a putative virulence factor of Leishmania parasites, and nucleoside diphosphate kinase, an enzyme with a critical role in nucleotide recycling, also associated with resistance in Leishmania strains. Compound 4a showed better binding affinity than the standard to these targets; furthermore, the molecular dynamic simulation studies further affirmed the stability of compound 4a, within the active site of the targets. In vitro, cysteine protease inhibitory activity (IC50 8.53 μM) using Bz-Arg-AMC hydrochloride fluorogenic peptide substrate established the promising potential of 4a as a cysteine protease inhibitor. Results: Computational ADMET analysis indicated appropriate pharmacokinetic profile and physicochemical characteristics for all members of the synthesized library. Conclusion: Both in vitro and in silico studies indicate that the synthesized imidazole carboxamides can act as potent hits and that N-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5- yl)benzo[d][1,3]-5-carboxamide-dioxole 4a can be an effective hit molecule which can be further developed into potent lead molecule (s) to fight Leishmania donovani.
- 27 December 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (48)
Synthesis and Design of New 1,3,4‐Oxadiazole Benzimidazole Hybrids as Potential Antibacterial Agents Against MRSA by Targeting FabI
The current investigation describes the synthesis of the 1,3,4‐oxadiazole benzimidazole hybrids 5 (a–m) as antibacterial agents against methicillin‐resistant Staphylococcus aureus (MRSA) by targeting the enoyl‐acyl carrier protein binding site of enoyl‐acyl carrier protein reductase (FabI). Compounds having better (2–6 µg/mL) minimum inhibitory concentrations (MIC) than ampicillin (100 µg/mL) in initial screening using the broth dilution method against S. aureus ( ATCC ‐29213) were further gauged for their antimicrobial potential against MRSA (ATCC 4330) using sultamicillin as a standard. 5‐(2‐(4‐Chlorophenyl)‐1 H ‐benzo[d]imidazol‐6‐yl)‐ N ‐phenyl‐1,3,4‐oxadiazol‐2‐amine ( 5a ) was found to be most potent against MRSA with a MIC of 6 µg/mL in comparison to sultamicillin (25 µg/mL). Furthermore, the time‐kill assay exhibited that compound 5a was bactericidal and demonstrated a high safety profile, as hemolysis caused in human red blood cells was insignificant (1.6%) at the concentration of 6 µg/mL (MIC × 3). To establish the molecular target of action, in silico molecular docking studies were performed against Sa FabI to reconnoiter the intervention of the molecules in the FAS‐II pathway. Compound 5a exhibited high binding affinity (−11.19) to the target; furthermore, the molecular dynamic simulation studies affirmed the stability of compound 5a , within the active site of the target. All compounds exhibited drug‐appropriate physicochemical characteristics and pharmacokinetic profiles as established by computational ADMET analysis. The study revealed that the synthesized library of small‐molecule oxadiazole benzimidazole hybrids holds promise for developing new antibacterial agents against MRSA infections.
- 27 December 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (48)
Synthesis and Design of New 1,3,4‐Oxadiazole Benzimidazole Hybrids as Potential Antibacterial Agents Against MRSA by Targeting FabI
The current investigation describes the synthesis of the 1,3,4‐oxadiazole benzimidazole hybrids 5 (a–m) as antibacterial agents against methicillin‐resistant Staphylococcus aureus (MRSA) by targeting the enoyl‐acyl carrier protein binding site of enoyl‐acyl carrier protein reductase (FabI). Compounds having better (2–6 µg/mL) minimum inhibitory concentrations (MIC) than ampicillin (100 µg/mL) in initial screening using the broth dilution method against S. aureus ( ATCC ‐29213) were further gauged for their antimicrobial potential against MRSA (ATCC 4330) using sultamicillin as a standard. 5‐(2‐(4‐Chlorophenyl)‐1 H ‐benzo[d]imidazol‐6‐yl)‐ N ‐phenyl‐1,3,4‐oxadiazol‐2‐amine ( 5a ) was found to be most potent against MRSA with a MIC of 6 µg/mL in comparison to sultamicillin (25 µg/mL). Furthermore, the time‐kill assay exhibited that compound 5a was bactericidal and demonstrated a high safety profile, as hemolysis caused in human red blood cells was insignificant (1.6%) at the concentration of 6 µg/mL (MIC × 3). To establish the molecular target of action, in silico molecular docking studies were performed against Sa FabI to reconnoiter the intervention of the molecules in the FAS‐II pathway. Compound 5a exhibited high binding affinity (−11.19) to the target; furthermore, the molecular dynamic simulation studies affirmed the stability of compound 5a , within the active site of the target. All compounds exhibited drug‐appropriate physicochemical characteristics and pharmacokinetic profiles as established by computational ADMET analysis. The study revealed that the synthesized library of small‐molecule oxadiazole benzimidazole hybrids holds promise for developing new antibacterial agents against MRSA infections.